Erik Max Wulff - Concepedia

Author

Erik Max Wulff

Also Known As

E M Wulff, E. M. Wulff, E.M Wulff, E.M. Wulff, ERIK M. WULFF, Erik M Wulff, Erik M. Wulff, Erik Max Wulff, Wulff, Erik Max

Publications

891

Citations

H-Index

Concepts

All Affiliations

Novo Nordisk (Denmark)University of Copenhagen Apigenex (Czechia)Central Drug Research Institute Center for Clinical & Basic Research

About

Erik Max Wulff is an author at Novo Nordisk (Denmark) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	249
2	Biochemistry	6	6	164
3	Health Sciences	5	5	169
4	Natural Sciences	1	1	33
5	Biomolecular Engineering	1	1	33

Erik Max Wulff

Publications

846

Citations

H-Index

Page 1

	Year	Citations
Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity Per Sauerberg, Ingrid Pettersson, Lone Jeppesen, Journal of Medicinal Chemistry	2002	142
Differential Influences of Peroxisome Proliferator–Activated Receptorsγ and -α on Food Intake and Energy Homeostasis Philip J. Larsen, Per Bo Jensen, Rikke V. Sørensen, Diabetes	2003	111
Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague–Dawley rats V. Jensen, Henning Hvid, Jesper Damgaard, Diabetology & Metabolic Syndrome	2018	89
Prediction of PPAR-α ligand-mediated physiological changes using gene expression profiles Klaus Stensgaard Frederiksen, Erik Max Wulff, Per Sauerberg, Journal of Lipid Research	2004	62
Molecular engineering of safe and efficacious oral basal insulin František Hubálek, Hanne H. F. Refsgaard, Sanne Gram-Nielsen, Nature Communications	2020	56
Antidyslipidemic action of fenofibrate in dyslipidemic–diabetic hamster model Farhan Rizvi, A. Puri, G.S. Bhatia, Biochemical and Biophysical Research Communications Metabolic SyndromeAntidyslipidemic ActionMedicineDiabetesPhysiology	2003	45
Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-γ) agonist balaglitazone Philip J. Larsen, Kirsten Lykkegaard, Leif K. Larsen, European Journal of Pharmacology Molecular PharmacologyMetabolic SyndromeBiochemistryMedicinePhysiology	2008	44
Improved insulin sensitivity and islet function after PPARδ activation in diabetic db/db mice Maria Sörhede Winzell, Erik Max Wulff, Grith Skytte Olsen, European Journal of Pharmacology Metabolic SyndromeInsulin SensitivityInsulin SignalingSignal TransductionMedicine	2009	40
Combination of the insulin sensitizer, pioglitazone, and the long‐acting GLP‐1 human analog, liraglutide, exerts potent synergistic glucose‐lowering efficacy in severely diabetic ZDF rats Philip J. Larsen, Erik Max Wulff, C. F. Gotfredsen, Diabetes Obesity and Metabolism	2008	36
Engineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320 Thomas Kjeldsen, František Hubálek, Tina M. Tagmose, Journal of Medicinal Chemistry	2020	36

Page 1